Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 128
- 主要终点
- Change on the height of the patients
研究概览
简要总结
This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 2 Weeks 至 54 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •IHs diagnosed by medical history and physical examination
- •no previous treatment with other medications
排除标准
- •a history or risk of asthma, reactive airway disease, impaired renal or liver function, heart defects or arrhythmia, hypotension and hypersensitivity to propranolol
- •Infants who did not adhere to the treatments or attend follow-up visits
- •Infants with other known risk factors for developmental delay or growth restriction, such as prematurity, small for gestational age, or other major congenital malformations, were also excluded
- •No other treatment was used during the oral propranolol course
研究组 & 干预措施
Propranolol treatment group
干预措施: propranolol (Drug)
结局指标
主要结局
Change on the height of the patients
时间窗: at the beginning of the treatment, at the end of treatment and 2 years after the treatment
we recorded the height of the patients in meters.
Change on the weight of the patients
时间窗: at the beginning of the treatment, at the end of treatment and 2 years after the treatment
we recorded the weight of the patients in kilograms.
次要结局
未报告次要终点